Joshua A Roth

ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 18

Top Venues

JCO oncology practice

Future oncology (London, England)

Blood advances

PloS one

University of Washington

University of Washington (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

University of Washington

United States

Affiliate Assistant Professor :: Department of Pharmacy

Fred Hutchinson Cancer Research Center

United States

Assistant Member :: Hutchinson Institute for Cancer Outcomes Research

Education History

University of Washington

United States

PHD :: Department of Pharmacy

Publications

Joshua A Roth, Makan Rahshenas, Grégoire Nowacki, Nihar Masurkar, Ahmed Shelbaya, Kentaro Tajima, Stephanie Dorman, Chiho Ono
A descriptive analysis of real-world oncology biosimilar use in Japan. Future oncology (London, England) (2024)
Patrick C DeMartino, Meredith B Haag, Aaron B Caughey, Joshua A Roth
A Budget Impact Analysis of Gene Therapy for Sickle Cell Disease: An Updated Analysis. Blood advances (2024)
Patrick C DeMartino, Meredith B Haag, Aaron B Caughey, Joshua A Roth
A budget impact analysis of gene therapy for sickle cell disease: an updated analysis. Blood advances 8 (17) (2024)
Wael Saber, Aasthaa Bansal, Lily Li, Bart L Scott, Lindsey R Sangaralingham, Viengneesee Thao, Joshua A Roth, Winona Wright, Lotte M G Steuten, Joseph A Pidala, Asmita Mishra, Richard T Maziarz, Peter Westervelt, Joseph P McGuirk, Corey S Cutler, Ryotaro Nakamura, Scott D Ramsey
Cost-Effectiveness of Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation for Older Patients With High-Risk Myelodysplastic Syndrome: Analysis of BMT CTN 1102. JCO oncology practice 20 (4) (2024)
Wael Saber, Aasthaa Bansal, Lily Li, Bart L Scott, Lindsey R Sangaralingham, Viengneesee Thao, Joshua A Roth, Winona Wright, Lotte M G Steuten, Joseph A Pidala, Asmita Mishra, Richard T Maziarz, Peter Westervelt, Joseph P McGuirk, Corey S Cutler, Ryotaro Nakamura, Scott D Ramsey
Cost-Effectiveness of Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation for Older Patients With High-Risk Myelodysplastic Syndrome: Analysis of BMT CTN 1102. JCO oncology practice (2024)
Wael Saber, Aasthaa Bansal, Lily Li, Bart L Scott, Lindsey R Sangaralingham, Viengneesee Thao, Joshua A Roth, Winona Wright, Lotte M G Steuten, Joseph A Pidala, Asmita Mishra, Richard T Maziarz, Peter Westervelt, Joseph P McGuirk, Corey S Cutler, Ryotaro Nakamura, Scott D Ramsey
Cost-Effectiveness of Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation for Older Patients With High-Risk Myelodysplastic Syndrome: Analysis of BMT CTN 1102. JCO oncology practice 20 (4) (2024)
Joshua A Roth, Makan Rahshenas, Grégoire Nowacki, Nihar Masurkar, Ahmed Shelbaya, Kentaro Tajima, Stephanie Dorman, Chiho Ono
A descriptive analysis of real-world oncology biosimilar use in Japan. Future oncology (London, England) (2024)
Grace E Fox, Mark Bernauer, Jennifer M Stephens, Bianca Jackson, Joshua A Roth, Ahmed Shelbaya
Clinical and Economic Value of a Biosimilar Portfolio to Stakeholders: An Integrative Literature Review. ClinicoEconomics and outcomes research : CEOR 16 (2024)
Joshua A Roth, Makan Rahshenas, Grégoire Nowacki, Nihar Masurkar, Ahmed Shelbaya, Kentaro Tajima, Stephanie Dorman, Chiho Ono
A descriptive analysis of real-world oncology biosimilar use in Japan. Future oncology (London, England) (2024)
Patrick C DeMartino, Meredith B Haag, Aaron B Caughey, Joshua A Roth
A budget impact analysis of gene therapy for sickle cell disease: an updated analysis. Blood advances 8 (17) (2024)
Grace E Fox, Mark Bernauer, Jennifer M Stephens, Bianca Jackson, Joshua A Roth, Ahmed Shelbaya
Clinical and Economic Value of a Biosimilar Portfolio to Stakeholders: An Integrative Literature Review. ClinicoEconomics and outcomes research : CEOR 16 (2024)
Zachary T Rivers, Joshua A Roth, Winona Wright, Sun Hee Rim, Lisa C Richardson, Cheryll C Thomas, Julie S Townsend, Scott D Ramsey
Translating an Economic Analysis into a Tool for Public Health Resource Allocation in Cancer Survivorship. MDM policy & practice 8 (1) (2023)
Zachary T Rivers, Joshua A Roth, Winona Wright, Sun Hee Rim, Lisa C Richardson, Cheryll C Thomas, Julie S Townsend, Scott D Ramsey
Translating an Economic Analysis into a Tool for Public Health Resource Allocation in Cancer Survivorship. MDM policy & practice 8 (1) (2023)
Joshua A Roth, Meghna S Trivedi, Stacy W Gray, Donald L Patrick, Debbie M Delaney, Kate Watabayashi, Paul Litwin, Parth Shah, Katherine D Crew, Monica Yee, Mary W Redman, Joseph M Unger, Vassiliki Papadimitrakopoulou, Judy Johnson, Karen Kelly, David R Gandara, Roy S Herbst, Dawn L Hershman, Scott D Ramsey
Patient Knowledge and Expectations About Return of Genomic Results in a Biomarker-Driven Master Protocol Trial (SWOG S1400GEN). JCO oncology practice 17 (11) (2021)
Joshua A Roth, Yong Yuan, Megan Othus, Mark D Danese, Samuel Wagner, John R Penrod, Scott D Ramsey
A comparison of mixture cure fraction models to traditional parametric survival models in estimation of the cost-effectiveness of nivolumab for relapsed small cell lung cancer. Journal of medical economics 24 (1) (2021)
Salvatore Fiorenza, David S Ritchie, Scott D Ramsey, Cameron J Turtle, Joshua A Roth
Value and affordability of CAR T-cell therapy in the United States. Bone marrow transplantation 55 (9) (2020)
Lia M Halasz, Shilpen A Patel, Jean A McDougall, Catherine Fedorenko, Qin Sun, Bernardo H L Goulart, Joshua A Roth
Intensity modulated radiation therapy following lumpectomy in early-stage breast cancer: Patterns of use and cost consequences among Medicare beneficiaries. PloS one 14 (9) (2019)
Joshua A Roth, Lisa Carter-Harris, Susan Brandzel, Diana S M Buist, Karen J Wernli
A qualitative study exploring patient motivations for screening for lung cancer. PloS one 13 (7) (2018)

Joshua A Roth

Publication Activity (10 Years)

Top Topics

Top Venues